Amgen Q1 2026 slides: six growth drivers fuel 24% expansion

Amgen reported Q1 2026 revenue of $8.6B, up 6% year over year, with non-GAAP EPS of $5.15 beating consensus by 7.3%. The company raised full-year 2026 guidance to $37.1B-$38.5B in revenue and $21.70-$23.10 in EPS, while Repatha, EVENITY, TEZSPIRE, rare disease, oncology, and biosimilars all posted strong growth. Shares still fell 2.43% after hours, likely reflecting investor concern over patent erosion and the durability of future growth.

Analysis

The market is treating this as a “good quarter, bad stock” setup because the headline print does not solve the real problem: durability of the next 12–24 months once legacy cash cows fade. What matters is that management is now forced to fund growth from a broader set of newer franchises, and that usually compresses confidence multiples before it re-rates them. The earnings beat is therefore less important than the emerging evidence that Amgen can replace expiring revenue with a diversified portfolio without sacrificing margin structure.

The second-order winner is the biotech platform itself: every incremental dollar of R&D now has a clearer payback path, which should support peers with late-stage obesity, immunology, or rare disease assets. The relative loser is any company dependent on a single mechanism or narrowly distributed launch — Amgen is demonstrating that scale, field force breadth, and manufacturing capacity are becoming more valuable than pure scientific novelty. In addition, stronger cash generation and a higher dividend increase the stock’s appeal to income buyers, but that also makes the name more bond-proxy-like, so it can lag on days when rates back up.

The key risk is that investors may be underestimating how much of the current growth is still “easy” adoption, versus true new-category creation. Repatha’s cardiometabolic opportunity looks large, but broad primary-prevention uptake is a reimbursement and prescriber-behavior battle that plays out over quarters, not weeks. MariTide is the real swing factor over the next 6–18 months: if the Phase 3 readout profile is merely competitive rather than clearly differentiated on efficacy/tolerability, the market will likely discount the obesity optionality hard.

Consensus may also be missing that the post-earnings selloff is not necessarily bearish; it can reflect investors rotating from “quality defensive” into higher-beta biotech catalysts. If management executes on pipeline milestones through year-end, the stock can re-rate on forward 2027 earnings instead of 2026, especially if tax-rate guidance and capex discipline persist. The current setup argues for patience on outright longs, but the asymmetry improves if the name is bought on further weakness into catalyst windows rather than chased after strength.

Key Decisions for Investors

• Go long AMGN on a 1–3 month horizon only on pullbacks below the post-earnings level; target a re-rating toward 24–25x forward earnings if guidance credibility holds, with downside limited by cash flow and dividend support.
• Pair trade: long AMGN / short a lower-quality single-asset biotech with near-term binary risk over the next 6–9 months; the thesis is that diversified commercial execution deserves a premium while pipeline-only names face financing and trial-risk compression.
• Buy AMGN call spreads into the next MariTide/Phase 3 catalyst window (6–12 months out) to express upside from obesity optionality without paying full equity delta; ideal if implied volatility remains elevated after the print.
• For income-oriented books, use AMGN as a defensive cash-flow compounder versus higher-beta pharma, but size smaller than usual because a disappointing obesity or cardiometabolic update could de-rate the multiple by 2–3 turns quickly.